Clinical trial
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human)…
NCT00473824 · ADMA Biologics, Inc., Industry · Terminated
Key facts
| NCT number | NCT00473824 |
|---|---|
| Title | Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation |
| Official title | A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients |
| Lead sponsor | ADMA Biologics, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation |
| Intervention type | Biological |
| Interventions | Hepatitis C Immune Globulin Intravenous (Human) 5% |
| Enrollment | 7 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | May 16, 2007 |
| Last update posted | Jul 30, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: